by April Breyer Menon | Nov 5, 2019
In an article for Biosimilar Development, Ha Kung Wong and Erica Norey discuss the potential impact of authorized biologics on the developing biosimilars market. The article draws upon experience with authorized generics in the small molecule drug market and...
by April Breyer Menon | Nov 4, 2019
On October 31, 2019, a Federal Circuit panel (Judges Moore, Reyna, and Chen), in Arthrex, Inc. v. Smith & Nephew, Inc., No. 2018-2140, held that the appointment of administrative patent judges (APJs) by the Secretary of Commerce under Title 35 violates the...
by April Breyer Menon | Oct 16, 2019
In an article for Bloomberg Law, Venable partner Ha Kung Wong discusses how the U.S. patent system and inter partes review (IPR) proceedings affect pharmaceutical innovation. The article can be viewed here.
by April Breyer Menon | Oct 1, 2019
In an article for MedCity News, Venable partner Ha Kung Wong discusses reasons for the slow uptake of biosimilars in the US. The article can be viewed here.
by April Breyer Menon | Sep 30, 2019
Biosimilar uptake has been low in the United States so far, with market shares for most biosimilars under 10%. Given the cost savings potential, trying to increase biosimilar uptake has been high on Congress’ agenda. There are many bills pending in Congress dealing...
by April Breyer Menon | Aug 15, 2019
Thus far 2019 has been an eventful year for patent law in the United States. Over the past seven months, the U.S. Supreme Court and the Court of Appeals for the Federal Circuit (the U.S. appellate court tasked with reviewing all district court patent decisions) have...